Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EGFR TKI alone versus addition of bevacizumab or radiotherapy after stable disease in EGFR-mutant NSCLC
ChiCTR1800019856Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital, Anhui Medical University
- Start
- Jan 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of bevacizumab in non-small cell lung cancer (NSCLC) (4 arms), sponsored by The First Affiliated Hospital, Anhui Medical University. Primary endpoint: Progression-free survival. Planned start Jan 2019; status: not yet recruiting.
02
Drugs
bevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR1800019856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800019856.